How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
NEW HAVEN , Conn., May 17 /PRNewswire/ -- Ikonisys Inc., the leadingdeveloper of automated cell-based diagnostic products, today announced thenon-exclusive sale to Michigan Institute of Urology, P.C. of its proprietaryIkoniscope(R) robotic microscopy platform and its oncoFISH(TM) bladderapplication. In conjunction with the Ikoniscope, oncoFISH bladder enablesautomated testing of cells found in urine specimens to aid in the detection ofbladder cancer. Earlier this year, oncoFISH bladder became the first fullyautomated oncology diagnostic test to be cleared for marketing by the UnitedStates Food and Drug Administration (FDA).
"The Ikoniscope is the only high-throughput 'plug-and-play' system on themarket, and we have found that it enables greater analytical sensitivity thanany other fluorescence in situ hybridization analysis system," said AlphonseSantino , M.D., President and CEO of Michigan Institute of Urology. "We arededicated to providing our patients with the most up-to-date, quality,cost-effective urologic care available, and are pleased to integrate theIkoniscope and the oncoFISH bladder cancer diagnostic assay into our serviceofferings."
"Michigan Institute of Urology is one of the oldest and the largestmulti-specialty urology practices in the state of Michigan, and we are verypleased that the practice will begin using our oncoFISH bladder diagnostictest to aid in improving the sensitivity, efficiency and cost-effectiveness ofmaking bladder cancer diagnoses," said Petros Tsipouras, M.D., Chairman andCEO of Ikonisys.
Ikonisys' suite of diagnostic products automates a standard buttime-consuming laboratory technique, fluorescence in situ hybridization(FISH), which identifies chromosome aberrations associated with variousdiseases. oncoFISH bladder detects aberrations for chromosomes 3, 7, 9, and17 in cells found in urine sediment to aid in the initial diagnosis of bladdercancer in patients with hematuria (blood in the urine) and the subsequentmonitoring for tumor recurrence in patients previously diagnosed with bladdercancer.
About Bladder Cancer
Bladder cancer is one of the most common cancers in the United States .More than 61,000 new cases of bladder cancer were diagnosed in 2006, accordingto the American Cancer Society, and most patients are monitored for recurrentdisease.